-+ 0.00%
-+ 0.00%
-+ 0.00%

EMA accepts Teva filing for Medincell long-acting olanzapine schizophrenia injection

PUBT·05/21/2026 17:24:26
Listen to the news
EMA accepts Teva filing for Medincell long-acting olanzapine schizophrenia injection
  • Medincell: EMA accepted Teva’s marketing authorization application for a monthly, long-acting subcutaneous olanzapine injection (TEV-’749) to treat schizophrenia in adults.
  • The filing is backed by a Phase 3 program including the SOLARIS study; the product is not yet approved in any market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260521567845) on May 21, 2026, and is solely responsible for the information contained therein.